Sep 2026· Journal of Immunotherapy and Precision Oncology· Vol 9, pp. 153 - 245· 1 citation· 724 references
Medicine
TL;DR
This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their clinical impact is limited by immune-related adverse events (irAEs), therapeutic resistance, and the lack of reliable predictive biomarkers, contributing to a shift from early promise to a therapeutic plateau. irAEs affect multiple organ systems and may lead to treatment interruption and significant morbidity. Emerging strategies emphasize phenotype-driven and steroid-sparing approaches to control toxicity while preserving antitumor efficacy. Concurrently, primary and acquired resistance remain major challenges, driven by tumor-intrinsic mechanisms, immune microenvironment alterations, and host factors. Furthermore, current biomarkers, including programmed cell death ligand 1 (PD-L1) expression and tumor mutation burden, demonstrate inconsistent predictive performance across tumor types. Advances in immune profiling, genomics, and microbiome research are enabling more precise patient stratification and informing novel therapeutic strategies, including rational combinations and targeted immunomodulation. This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability. Together, these advances position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology. Graphical Abstract
The central conclusion of this review is that effective clinical translation will necessitate a paradigm shift from discrete pathway inhibition toward integrated precision immuno-oncology strategies that combine molecular profiling, immune-contexture analysis, and mechanism-based combination therapies.
Yu-Yu Xu, Huiling Shen· Iranian journal of immunolog...· 0 citations
This review focuses on targetable biomarker classes that link resistance biology to therapeutic sensitization across cancers, including transcription factors, genomic alterations, immune checkpoint proteins and metabolic regulators, and discusses the mechanistic basis of resistance-associated biomarkers.
Chao Wang, Dong Yang· Frontiers in Cell and Develo...· 0 citations
This review examines the evolving landscape of ICI‐based combination therapies, including regimens that combine ICI with chemotherapy, targeted therapy, antibody–drug conjugates, antiangiogenic agents, and radiotherapy, which have expanded first‐line treatment options across multiple solid tumors and, in selected setti...
Immune checkpoint inhibitors have changed cancer management. However, immune-related adverse events (irAEs) can disrupt treatment and limit effective combination strategies. The standard of care tends to involve broad immunosuppression, which may compromise antitumor immunity and fail to address the dominant biology of...
Zhen Sun, Xiao-Yi Yang, Wei-Ming Shen et al.· TIPS - Trends in Pharmacolog...· 1 citation
This review integrates the major tumor-intrinsic and tumor-extrinsic mechanisms that drive ICI resistance, including defective antigen presentation, impaired interferon signaling, oncogenic and epigenetic immune escape programs, metabolic rewiring, suppressive myeloid and stromal circuits, abnormal vasculature, and pro...
R. Karataş, Yaren Alras, Sarenur Teki̇ner et al.· Immunologic research· 0 citations
ABSTRACT Introduction Immunotherapy resistance is mediated by mechanisms distinct from those underlying conventional chemotherapy, including tumor-intrinsic alterations, an immunosuppressive tumor microenvironment, and other host factors, that collectively constrain durable responses. Areas covered This review provides...
Kenneth K. W. To, Ting-Nan Ma, Long-Ling Wang et al.· Expert opinion on therapeuti...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.